<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543127</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2006-10</org_study_id>
    <nct_id>NCT00543127</nct_id>
  </id_info>
  <brief_title>Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole</brief_title>
  <official_title>Phase III Trial Comparing Efficacy and Tolerance of Fulvestrant for 3 Years (y) Combined With Anastrozole 5 y Versus Anastrozole 5 y as Adjuvant Hormonotherapy in Postmenopausal With Early Breast Cancer and Positive Hormone Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postmenopausal women with hormone receptor positive and negative Her2 tumours.

      Before randomization, the patients will be stratified according to the center, positive nodes
      (0 vs. 1-3 vs. ≥4), previous chemotherapy (yes vs no) and hormonal receptors status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is expected that disease-free survival for patients receiving Anastrozole alone for 5
      years will be up to 90%. An increase of 3% in disease-free survival (DFS) is expected in the
      arm of Fulvestrant plus Anastrozole, i.e a DFS of up to 93%. They will be required 1358
      patients per treatment group (i.e, 2716 patients in total) to give 80% power, alfa bilateral
      0.05, and OR 0.6888. Assuming 5% screening failures 2852 patients are required to enter the
      study. In Jun-2010 the recruitment was stopped due to lack of support of the financier based
      on the result of Faslodex® and Arimidex® in Combination Trial (FACT-trial), comparing
      Fulvestrant + Anastrozole vs Anastrozole alone in 1st relapse showed no difference in time to
      progression at more than 40 months follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unjustified decision of company that funded the trial.
  </why_stopped>
  <start_date type="Actual">November 2007</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS) Events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Disease-free survival (DFS) has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Specific Survival (BCsS) Events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>BCsS events has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to BCsS in patients treated with anastrozole for 5 years.
BCsS event is defined as the death from breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Event</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>OS event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
OS event is defined as the death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence (TR) Event</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>TR event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
TR event is defined as the evidence of breast cancer recurrence (local and/or distant recurrence of breast cancer, does not include second primary malignancies or deaths from any cause).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">870</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Fulvestrant + Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
    <arm_group_label>Fulvestrant + Anastrozole</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg oral Anastrozole per day during 5 years.</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_label>Fulvestrant + Anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histological documentation of breast cancer.

          2. Stage I, II, IIIA and IIIC* invasive breast cancer. One of these two characteristics
             must be fulfilled:

               -  N+

               -  T &gt; 1cm *Eligible patients T1-T3 and pN3a (patients with metastasis in
                  infraclavicular nodes would not be eligible)

          3. Local treatment with curative intention:

               -  mastectomy or tumour excision with free margins + radiotherapy

               -  axillary lymphadenectomy or sentinel node biopsy

          4. Positive hormone receptors (Estrogen Receptor [ER]+ and/or Progesterone Receptor
             [PR]+) in primary tumour tissue as measured by a central laboratory

          5. Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, defined as
             immunohistochemistry (IHC) 0 or 1+ or negative fluorescence in situ hybridization
             (FISH) (in the event of IHC 2+ or 3+)

          6. Postmenopausal women, defined as women meeting any of the following criteria:

               -  Age ≥ 60 years

               -  Age ≥ 45 years with amenorrhea ≥ 12 months in the moment of breast cancer
                  diagnosis and an intact uterus

               -  Prior bilateral ovariectomy

               -  In case previous hysterectomy, follicle stimulating hormone (FSH) and estradiol
                  levels within the postmenopausal range (using local laboratory ranges)* * In
                  patients previously treated with a luteinizing hormone releasing hormone (LH-RH)
                  analogue, the last extended release formulation should have been administered
                  more than 6 months before randomisation, and menses must not have reappeared.

          7. A World Health Organization (WHO) performance status of 0, 1, or 2.

          8. Age &gt; 18 years

        Exclusion criteria:

          1. Presence of metastatic disease or bilateral invasive cancer

          2. ER and Progesterone Receptor (PR) negative breast cancer

          3. HER2-positive breast cancer, defined as FISH+

          4. Treatment with a non-approved or experimental drug within 4 months of randomisation

          5. Current malignancy or previous malignancy in the past 5 years (other that breast
             cancer or basal cell or squamous cell carcinoma of the skin or carcinoma in situ of
             the cervix)

          6. Pregnant or nursing patients

          7. Any of the following laboratory values within 3 months of randomisation:

               -  Platelets &lt; 100 x 109/L

               -  Total bilirubin &gt; 1.5 x Upper limit of reference range (ULRR)**

                  ** Patients with documented Gilbert syndrome may be included in this trial

               -  Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) &gt; 2.5 x ULRR

               -  A history of:

               -  hemorrhagic diathesis (i.e. Disseminated Intravascular Coagulation [DIC],
                  coagulation factor deficiency) or

               -  long-term anticoagulant treatment (except for anti-platelet aggregants and
                  low-dose warfarin; see section 3.7)

          8. A history of hypersensitivity to the active ingredient or inactive excipients of
             fulvestrant, aromatase inhibitors, or castor oil

          9. Any concomitant severe disease advising against patient participation in the trial o
             that may jeopardize compliance with the trial protocol, such as uncontrolled heart
             disease, uncontrolled diabetes mellitus, or uncontrolled severe infections

         10. Hormone replacement therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Centro Oncológico de Galicia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Los Lirios</name>
      <address>
        <city>Alcoy</city>
        <state>Alicante</state>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elda</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Usp San Jaime</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03180</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrevieja Salud Ute</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Agustín de Avilés</name>
      <address>
        <city>Avilés</city>
        <state>Asturias</state>
        <zip>33400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Municipal de Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catalá D'Oncología L'Hospitalet</name>
      <address>
        <city>L'hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castellón de La Plana</city>
        <state>Castellón</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>Donostia-san Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologikoa</name>
      <address>
        <city>Donostia-san Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <state>Huesca</state>
        <zip>22300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Insular-Materno Infantil</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>LAS Palmas</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa CRUZ DE Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Valme</name>
      <address>
        <city>Dos Hermanas</city>
        <state>Sevilla</state>
        <zip>41700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluís Alcanyis</name>
      <address>
        <city>Xátiva</city>
        <state>Valencia</state>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta Del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSPITAL UNIVERSITARI DE GIRONA DR. JOSEP TRUETA (ICO de Girona)</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (Hospital Madrid Norte Sanchinarro)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau de Vilanova de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Description Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <results_first_submitted>December 13, 2017</results_first_submitted>
  <results_first_submitted_qc>January 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2019</results_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>870 patients were recruited, from them, 437 were randomized to Anastrozole (A) and 433 to A plus Fulvestrant (F), but 18 patients (3 in A arm and 15 in arm A+F) never received treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fulvestrant + Anastrozole</title>
          <description>Fulvestrant + Anastrozole: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
        </group>
        <group group_id="P2">
          <title>Anastrozole</title>
          <description>Anastrozole: 1 mg oral Anastrozole per day during 5 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="350"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fulvestrant + Anastrozole</title>
          <description>Fulvestrant + Anastrozole: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
        </group>
        <group group_id="B2">
          <title>Anastrozole</title>
          <description>Anastrozole: 1 mg oral Anastrozole per day during 5 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="433"/>
            <count group_id="B2" value="437"/>
            <count group_id="B3" value="870"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="40" upper_limit="86"/>
                    <measurement group_id="B2" value="62" lower_limit="44" upper_limit="86"/>
                    <measurement group_id="B3" value="62" lower_limit="40" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="433"/>
                    <measurement group_id="B2" value="437"/>
                    <measurement group_id="B3" value="870"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breast Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Conservative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="310"/>
                    <measurement group_id="B3" value="613"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mastectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Axillary surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Axillary dissection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="539"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sentinel Node Biopsy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Adjuvant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="517"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neoadjuvant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neoadjuvant + Adjuvant</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous radiotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>YES</title>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="695"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NO</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histopathologic type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Invasive Ductal Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="337"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="683"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Invasive Lobular Carcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic grade</title>
          <description>The grade of a breast cancer is a prognostic factor and is representative of the &quot;aggressive potential&quot; of the tumor. In a broad generalization, &quot;low grade&quot; cancers tend to be less aggressive than &quot;high grade&quot; cancers. There are 3 grades: Grade I tumors have a total score of 3-5, Grade II tumors have a total score of 6-7 and Grade III tumors have a total score of 8-9. Grade X is unknown result.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="451"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade X</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor size</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0.08" upper_limit="10"/>
                    <measurement group_id="B2" value="2" lower_limit="0.0" upper_limit="15"/>
                    <measurement group_id="B3" value="2" lower_limit="0.0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Final diagnosis tumor size</title>
          <description>Using the Tumour Node Metastasis staging system (TNM) after surgery, the “T” plus a number (0 to 4) is used to describe the size of the tumor. The T0 means the lower size, and the T4 means the higher size. TX means unknown.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>T1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="463"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="368"/>
                  </measurement_list>
                </category>
                <category>
                  <title>T3-T4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>TX</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nodal status</title>
          <description>The “N” in the TNM staging stands for lymph nodes. NX: not evaluated. N0: No cancer was found / Only areas of cancer smaller than 0.2 mm. N1: The cancer has spread to 1 to 3 axillary lymph nodes and/or the internal mammary lymph nodes. N2: The cancer has spread to 4 to 9 axillary lymph nodes, or it has spread to the internal mammary lymph nodes, but not the axillary lymph nodes. N3: The cancer has spread to 10 or more axillary lymph nodes, or it has spread to the lymph nodes located under the clavicle, or collarbone. It may have also spread to the internal mammary lymph nodes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>N0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="414"/>
                  </measurement_list>
                </category>
                <category>
                  <title>N1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>N2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>N3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NX</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS) Events</title>
        <description>Disease-free survival (DFS) has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Primary statistical analyses of the efficacy outcome variables will be based on an intent-to-treat (ITT) method and will include all randomised patients</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant + Anastrozole: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS) Events</title>
          <description>Disease-free survival (DFS) has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause.</description>
          <population>Primary statistical analyses of the efficacy outcome variables will be based on an intent-to-treat (ITT) method and will include all randomised patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Cancer Specific Survival (BCsS) Events</title>
        <description>BCsS events has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to BCsS in patients treated with anastrozole for 5 years.
BCsS event is defined as the death from breast cancer.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Analyses of the efficacy outcome variables will be based on an intent-to-treat (ITT) method and will include all randomised patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant + Anastrozole: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Cancer Specific Survival (BCsS) Events</title>
          <description>BCsS events has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to BCsS in patients treated with anastrozole for 5 years.
BCsS event is defined as the death from breast cancer.</description>
          <population>Analyses of the efficacy outcome variables will be based on an intent-to-treat (ITT) method and will include all randomised patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Event</title>
        <description>OS event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
OS event is defined as the death from any cause.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Statistical analyses of the efficacy outcome variables will be based on an intent-to-treat (ITT) method and will include all randomised patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant + Anastrozole: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Event</title>
          <description>OS event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
OS event is defined as the death from any cause.</description>
          <population>Statistical analyses of the efficacy outcome variables will be based on an intent-to-treat (ITT) method and will include all randomised patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrence (TR) Event</title>
        <description>TR event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
TR event is defined as the evidence of breast cancer recurrence (local and/or distant recurrence of breast cancer, does not include second primary malignancies or deaths from any cause).</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant + Anastrozole</title>
            <description>Fulvestrant + Anastrozole: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole: 1 mg oral Anastrozole per day during 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence (TR) Event</title>
          <description>TR event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.
TR event is defined as the evidence of breast cancer recurrence (local and/or distant recurrence of breast cancer, does not include second primary malignancies or deaths from any cause).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) will be recorded from the date informed consent is signed, during the treatment period, and for up to 8 weeks after the last injection in patients randomised to fulvestrant if this patient does not continue with anastrozole, or up to 30 days after the last tablet when this is the last study treatment received by the patient.</time_frame>
      <desc>These Adverse Events are by patient (not per cycle). Only grades 2, 3 and 4 are specified.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fulvestrant + Anastrozole</title>
          <description>Fulvestrant + Anastrozole: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.</description>
        </group>
        <group group_id="E2">
          <title>Anastrozole</title>
          <description>Anastrozole: 1 mg oral Anastrozole per day during 5 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTC Version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="415"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>chronic lymphocytic leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>lymphoblastic leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hemorrhage, CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hemorrhage, gi - colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hemorrhage, gi - stomach</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding associated with surgery, intra-operative or postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Conduction abnormality/atrioventricular heart block - av block-second degree mobitz type ii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Angor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>dilated cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>goitre</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Gastritis (including bile reflux gastritis)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Ileus, gi (functional obstruction of bowel, i.e., neuroconstipation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rectum cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Transverse colon adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Perforation, gi - appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Ulcer, gi - duodenum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastrointestinal abdomen nos pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastric difuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>acute hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>pancreas cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutrophils (anc &lt;1.0 x 109</sub_title>
                <description>pulmonary/upper respiratory - lung (pneumonia)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils dermatology/skin skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils - pulmonary/upper respiratory bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils - pulmonary/upper respiratory lung (pneumonia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils - pulmonary/upper respiratory upper airway nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils - sexual/reproductive function vagina and vulv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - cardiovascular heart (endocarditis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - gastrointestinal appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - gastrointestinal dental-tooth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - pulmonary/upper respiratory lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - renal/genitourinary urinary tract nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils - renal/genitourinary kidney</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or grade 1 or 2 neutrophils - renal/genitourinary urinary tract nos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>arthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Other: tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Musculoskeletal back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Musculoskeletal bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Musculoskeletal joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Musculoskeletal neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Neuropathy: craneal - cn vi downward, inward movement of eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Secondary malignancy - possiby related to cancer treatment, specify: kidney cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy - possiby related to cancer treatment, specify: uterine cervix cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Breast nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Microcalcification in breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/upper respiratory chest/thorax nos pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Induration/fibrosis (skin and subcutaneous tissue)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>t-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTC Version 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="415"/>
                <counts group_id="E2" subjects_affected="197" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="415"/>
                <counts group_id="E2" events="58" subjects_affected="58" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="415"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="415"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="415"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="415"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesterolemia)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="415"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>LDL-cholesterol high</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="415"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal bone pain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="415"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Musculoskeletal joint pain</sub_title>
                <counts group_id="E1" events="83" subjects_affected="83" subjects_at_risk="415"/>
                <counts group_id="E2" events="81" subjects_affected="81" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Miguel Martin</name_or_title>
      <organization>Department of Medical Oncology, Hospital Universitario Gregorio Marañón</organization>
      <email>miguel.martin@salud.madrid.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

